Indication
Spinal muscular atrophy
Spinal muscular atrophy is a rare, hereditary neuromuscular disorder primarily caused by biallelic mutations or deletions in the *SMN1* gene, leading to a deficiency of survival motor neuron protein. Read more about Spinal muscular atrophy
5 drugs 5 manufacturers
Drugs that treat it
Common Spinal muscular atrophy therapies.
ZOLGENSMA (onasemnogene abeparvovec-xioi)
EVRYSDI (risdiplam)
ITVISMA (onasemnogene abeparvovec-brve)
ISEMBYLD (apitegromab-mstn)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSpinal muscular atrophy is a rare, hereditary neuromuscular disorder primarily caused by biallelic mutations or deletions in the *SMN1* gene, leading to a deficiency of survival motor neuron protein.
This deficit results in the progressive degeneration and loss of lower motor neurons within the anterior horn of the spinal cord and lower brainstem.
Pathophysiologically, the disease manifests as symmetric, progressive muscle weakness and wasting that predominantly impacts proximal limb muscles, axial musculature, and respiratory muscles.
Clinical severity spans a broad continuum—from severe infantile-onset weakness with early respiratory failure to milder juvenile or adult-onset forms that impair ambulation.
- nih.gov
Spinal muscular atrophy is a rare, hereditary neuromuscular disorder primarily caused by biallelic mutations or deletions in the *SMN1* gene, leading to a deficiency of survival motor neuron protein This deficit results in the progressive degeneration and loss of lower motor neurons within the anterior horn of the spinal cord and lower brainstem Clinical severity spans a broad continuum—from severe infantile-onset weakness with early respiratory failure to milder juvenile or adult-onset forms th...
- medlineplus.gov
This deficit results in the progressive degeneration and loss of lower motor neurons within the anterior horn of the spinal cord and lower brainstem Pathophysiologically, the disease manifests as symmetric, progressive muscle weakness and wasting that predominantly impacts proximal limb muscles, axial musculature, and respiratory muscles
- medlineplus.gov
Pathophysiologically, the disease manifests as symmetric, progressive muscle weakness and wasting that predominantly impacts proximal limb muscles, axial musculature, and respiratory muscles
- medlineplus.gov
Clinical severity spans a broad continuum—from severe infantile-onset weakness with early respiratory failure to milder juvenile or adult-onset forms that impair ambulation
Personalize your experience
Follow Spinal muscular atrophy and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.